• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 9
  3. Author

Online ISSN: 2515-8260

Volume7, Issue9

A prospective study of Benefits and risk of paclitaxel drug in the treatment of femoropopliteal artery disease:

    Dr. Mohammed Hidayathulla , Dr. Azhar Ali Syed , Dr. Syeda Tasneem Kausar

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 9, Pages 3588-3597

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Introduction: Femoro-popliteal  arterial  disease  is  a  common  vascular  condition and Various  methods  of  revascularization  have been  tried  which  includes  simple  balloon  angioplasty,  debulking techniques ,  stent  implantation ,  and  recently  the  drug  eluting  balloons. Paclitaxel  drug  eluting  balloons  are  more  promising  in  the  approach  to treat  femoro-popliteal  arterial  disease .
Material and Methods: The present study from march 2016 to january 2018 was conducted on 25 cases prospectively in patients admitted to the Department of cardiology sri jayadeva institute of cardiovascular sciences and research center, Bangaluru (Karnataka). femoral  artery  using  cross  over  sheath  VascuQol – 6  disease  specific  health related  quality  of  life  questionnaire  post  procedure .     
Results: A  success  rate  of  92%  was  recorded  and  patients  treated  with DCB  showed  significantly  higher  primary  patency  of  the  affected vessel. The  current  study  reveals  that  vascuQoL-6  score  used  to assess  the  quality  of  life  of  the  patient  with  peripheral  arterial  disease  before  and  after  the  intervention  improved  and  it  is  statistically  significantly.
Conclusion: We conclude that Use  of  paclitaxel  drug  coating  balloon  is  safe  and  efficacious  in treating  femoro-popliteal  arterial  disease. Restenosis  which  was  noted  in  8%  of  our  cases  can be  successfully  managed  with  percutaneous  transluminal  angioplasty  using  same  DCB.
Keywords:
  • PDF (408 K)
  • XML
(2021). A prospective study of Benefits and risk of paclitaxel drug in the treatment of femoropopliteal artery disease:. European Journal of Molecular & Clinical Medicine, 7(9), 3588-3597.
Dr. Mohammed Hidayathulla , Dr. Azhar Ali Syed , Dr. Syeda Tasneem Kausar. "A prospective study of Benefits and risk of paclitaxel drug in the treatment of femoropopliteal artery disease:". European Journal of Molecular & Clinical Medicine, 7, 9, 2021, 3588-3597.
(2021). 'A prospective study of Benefits and risk of paclitaxel drug in the treatment of femoropopliteal artery disease:', European Journal of Molecular & Clinical Medicine, 7(9), pp. 3588-3597.
A prospective study of Benefits and risk of paclitaxel drug in the treatment of femoropopliteal artery disease:. European Journal of Molecular & Clinical Medicine, 2021; 7(9): 3588-3597.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 58
  • PDF Download: 106
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus